Months after Regeneron secured FDA approval for 12-week Eylea regimen, Novartis buys speedy US review for its rival
Novartis’ brolucizumab could do to Regeneron’s Eylea what the flagship eye treatment did to Roche’s Lucentis, some experts have predicted. Vas Narasimhan has shouted from the rooftops the promise of brolucizumab even before his elevation to Novartis chief. On Monday, Novartis came one step closer to launching its challenge to Regeneron’s formidable blockbuster, securing a speedy review for brolucizumab for use in wet age-related macular degeneration (AMD), setting it up for approval by the end of this year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.